Novocure reports Q4 EPS (61c), consensus (34c)

Reports Q4 revenue $161.27M, consensus $161.3M.”Entering 2024, our team was focused on three objectives grow our core business treating glioblastoma, launch in non-small cell lung cancer, and deliver on the promise of our clinical pipeline. I am proud to say we have successfully achieved all three goals,” said Ashley Cordova, CEO Novocure (NVCR). “2025 is a defining year for Novocure as we enter a new era with a multi-indication platform propelled by positive Phase 3 data in three indications,one FDA-approved and two advancing toward regulatory submission. We believe we are positioned to transform patient outcomes across multiple high-need oncology indications.”